Back
London
WeeklyBUY
0EDE
0EDE.L
NXP SEMICONDUCTORS NV NXP SEMIC

Latest update

$232

Updated: Apr 28, 2026, 9:58 AM UTC

Browsing public data

Metrics

Loading fundamentals

Pulling sales, cash, and growth data for 0EDE.L.

Thesis

Why this read

The weekly trend is intact above 221, and the pullback-to-21-EMA dynamic offers a defined tactical entry with stop near 215. However, the negative earnings growth and rich multiple mean this is explicitly a shorter-term timing call riding markup momentum, not a fundamental value case. I am treating this as a high-risk, lower-confidence setup where the technical structure is bullish but the fundamental deck is weak—appropriate sizing and tight risk management are essential.

Long-term thesis

0EDE.L (RELX Group) operates at the intersection of digital information services, analytics, and decision tools for professional markets—positioned to benefit from the secular shift toward data-driven decision making in healthcare, legal, risk, and scientific research as AI amplifies the value of proprietary structured data.

45opportunity
Mature5y horizon

Demand Gap

Professional information markets are largely digitized but AI-native competitors and open-source alternatives threaten pricing power; the gap lies in whether RELX can monetize AI-enhanced products faster than commoditization erodes legacy subscription models over 2-5 years.

Dependency Chain

  1. 1Enterprise and government spending on risk mitigation and compliance grows → demand for LexisNexis legal/risk analytics and Reed Exhibitions event data expands → RELX's subscription-based platforms capture recurring revenue
  2. 2Healthcare and life sciences R&D complexity increases → need for ClinicalTrials.gov, Embase, and pharma analytics rises → RELX's Scientific, Technical & Medical division owns critical infrastructure

Must be true

  • Enterprise customers continue to accept annual price increases on subscription products without significant churn
  • RELX successfully integrates AI features into existing workflows rather than seeing disruption from well-funded AI-native competitors entering legal/risk/scientific verticals

Thesis broken if

  • Accelerated customer churn or contract renegotiations materially below historical renewal rates in any core division
  • Open-source or VC-backed AI tools achieve functional parity with LexisNexis or RELX healthcare products at dramatically lower price points

History

Analysis timeline
1 runs

Jan 21, 1970

Latest

Updated Apr 28, 2026, 9:58 AM UTC

WeeklyBUY
Confidence55% · Medium

Price at review

$232

Price sits 4.1% above weekly 21 EMA with strong 20-day momentum of 21.4% and volume running 113% of trend—technical structure is constructive. However, with earnings imminent in one day and P/E at 28.9x with negative earnings growth (-6.8%), this is a tactical momentum call with compressed risk/reward, not a high-conviction fundamental entry.